Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a note issued to investors on Monday. The brokerage set a "hold" rating on the medical research company's stock.

CTSO has been the subject of several other research reports. HC Wainwright reissued a "neutral" rating and set a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital restated a "buy" rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $4.67.

Cytosorbents Trading Up 0.5 %

Shares of CTSO traded up $0.01 during mid-day trading on Monday, reaching $1.08. The stock had a trading volume of 81,791 shares, compared to its average volume of 288,467. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.61. The firm has a market cap of $58.78 million, a price-to-earnings ratio of -2.99 and a beta of 0.78. The business's fifty day moving average is $1.06 and its 200 day moving average is $1.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Remove Ads

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in Cytosorbents in the 4th quarter valued at about $30,000. Northern Trust Corp grew its stake in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after acquiring an additional 16,701 shares in the last quarter. Avenir Corp grew its stake in Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after purchasing an additional 118,387 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Cytosorbents during the 4th quarter worth about $99,000. Finally, Renaissance Technologies LLC raised its position in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after purchasing an additional 8,400 shares in the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.